share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/08/27 15:35

Moomoo AI 已提取核心訊息

Nukkleus has received multiple non-compliance notifications from Nasdaq, including the latest on August 22, 2024, regarding failure to file Q2 2024 Form 10-Q. The company faces three additional listing compliance issues: trading below $1.00 per share, market value of publicly held shares below $15 million, and market value of listed securities below $50 million.The company must submit a compliance plan to Nasdaq by October 21, 2024. If accepted, Nasdaq may grant an extension until February 17, 2025, to regain compliance. For the bid price issue, the company has until November 4, 2024, while the market value requirements must be met by November 12, 2024.While working to file the Form 10-Q and address these compliance issues, Nukkleus's common stock continues to trade on the Nasdaq Global Market. However, there is no guarantee the company will regain compliance within prescribed timeframes or receive additional extensions.
Nukkleus has received multiple non-compliance notifications from Nasdaq, including the latest on August 22, 2024, regarding failure to file Q2 2024 Form 10-Q. The company faces three additional listing compliance issues: trading below $1.00 per share, market value of publicly held shares below $15 million, and market value of listed securities below $50 million.The company must submit a compliance plan to Nasdaq by October 21, 2024. If accepted, Nasdaq may grant an extension until February 17, 2025, to regain compliance. For the bid price issue, the company has until November 4, 2024, while the market value requirements must be met by November 12, 2024.While working to file the Form 10-Q and address these compliance issues, Nukkleus's common stock continues to trade on the Nasdaq Global Market. However, there is no guarantee the company will regain compliance within prescribed timeframes or receive additional extensions.
Nukkleus已經收到了來自納斯達克的多次不合規通知,包括最新的通知是在2024年8月22日,涉及未能提交2024年第二季度的10-Q表格。該公司面臨三項額外的上市合規問題:每股交易價格低於1.00美元,公衆持有的股票市值低於1500萬,以及上市證券的市值低於5000萬。該公司必須在2024年10月21日前向納斯達克提交合規計劃。如果被接受,納斯達克可能會延長至2025年2月17日,以恢復合規。對於買盤價問題,該公司有直到2024年11月4日的時間,而市值要求必須在2024年11月12日之前滿足。在努力提交10-Q表格並解決這些合規問題的同時,Nukkleus的普通股仍在納斯達克全球市場交易。然而,無法保證該公司會在規定的時間框架內恢復合規或獲得額外的延長。
Nukkleus已經收到了來自納斯達克的多次不合規通知,包括最新的通知是在2024年8月22日,涉及未能提交2024年第二季度的10-Q表格。該公司面臨三項額外的上市合規問題:每股交易價格低於1.00美元,公衆持有的股票市值低於1500萬,以及上市證券的市值低於5000萬。該公司必須在2024年10月21日前向納斯達克提交合規計劃。如果被接受,納斯達克可能會延長至2025年2月17日,以恢復合規。對於買盤價問題,該公司有直到2024年11月4日的時間,而市值要求必須在2024年11月12日之前滿足。在努力提交10-Q表格並解決這些合規問題的同時,Nukkleus的普通股仍在納斯達克全球市場交易。然而,無法保證該公司會在規定的時間框架內恢復合規或獲得額外的延長。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息